Chemomab Therapeutics logo

Chemomab Therapeutics share price today

(CMMB)

Chemomab Therapeutics share price is $1.71 & ₹145.69 as on 25 Dec 2024, 2.30 'hrs' IST

$1.71

0.06

(3.82%)

Market is closed - opens 8 PM, 26 Dec 2024

View live Chemomab Therapeutics share price in Dollar and Rupees. Guide to invest in Chemomab Therapeutics from India. Also see the sentimental analysis on Indian investors investing in Chemomab Therapeutics. Get details on the Indian mutual funds that are investing in Chemomab Therapeutics. Get Analyst recommendations and forecasts along with all the Chemomab Therapeutics's financials.

Chemomab Therapeutics share price movements

  • Today's Low: $1.64
    Today's High: $1.75

    Day's Volatility :6.29%

  • 52 Weeks Low: $0.46
    52 Weeks High: $2.55

    52 Weeks Volatility :81.96%

Chemomab Therapeutics Returns

PeriodChemomab Therapeutics LtdSector (Health Care)Index (Russel 2000)
3 Months
9.11%
-9.0%
0.0%
6 Months
76.43%
-4.6%
0.0%
1 Year
223.29%
3.0%
0.0%
3 Years
-75.39%
0.0%
-21.1%

Chemomab Therapeutics Key Statistics

in dollars & INR

Previous Close
$1.65
Open
$1.68
Today's High
$1.75
Today's Low
$1.64
Market Capitalization
$32.3M
Today's Volume
$126.0K
52 Week High
$2.55
52 Week Low
$0.46
Revenue TTM
$0.0
EBITDA
$-16.0M
Earnings Per Share (EPS)
$-0.94
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-93.8%

How to invest in Chemomab Therapeutics from India?

It is very easy for Indian residents to invest directly in Chemomab Therapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Chemomab Therapeutics stock in both Indian Rupees (INR) and US Dollars (USD). Search for Chemomab Therapeutics or CMMB on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Chemomab Therapeutics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Chemomab Therapeutics shares which would translate to 0.498 fractional shares of Chemomab Therapeutics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Chemomab Therapeutics, in just a few clicks!

Returns in Chemomab Therapeutics for Indian investors in Rupees

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Chemomab Therapeutics investment value today

Current value as on today

₹3,24,880

Returns

₹2,24,880

(+224.88%)

Returns from Chemomab Therapeutics Stock

₹2,22,642 (+222.64%)

Dollar Returns

₹2,239 (+2.24%)

Indian investors sentiment towards Chemomab Therapeutics

357%

Period: Sep 26, 2024 to Dec 25, 2024. Change in 30 Days versus previous period

Search volume for Chemomab Therapeutics on INDmoney from India has grown in the last 30 days as on Dec 26, 2024. 357% more investors are searching Chemomab Therapeutics in the last 30 days versus the previous period.

Global Institutional Holdings in Chemomab Therapeutics

    Analyst Recommendation on Chemomab Therapeutics

    Buy

      75%Buy

      25%Hold

      0%Sell

    Based on 8 Wall street analysts offering stock ratings for Chemomab Therapeutics(by analysts ranked 0 to 5 stars)

    Based on 8 analyst
    • Current
    • 1M Ago
    • 3M Ago
    Buy
    6
    6
    6
    Hold
    2
    2
    2
    Sell
    0
    0
    0

    Analyst Forecast on Chemomab Therapeutics

    What analysts predicted

    Upside of 367.84%

    Current:

    $1.71

    Target:

    $8.00

    Insights on Chemomab Therapeutics

    • Price Movement

      In the last 6 months, CMMB stock has moved up by 71.3%
    • CMMB vs VRTX (3 yr)

      In the last 3 years, Vertex Pharmaceuticals Incorporated has given 25.2% return, outperforming this stock by 102.5%

    Chemomab Therapeutics Technicals Summary

    Sell

    Neutral

    Buy

    Chemomab Therapeutics is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

    Chemomab Therapeutics Vs Peers

    Company Name1 Month6 Month1 Year3 Years5 Years
    Chemomab Therapeutics Ltd
    7.74%
    76.43%
    223.29%
    -75.39%
    -99.52%
    Regeneron Pharmaceuticals, Inc.
    -5.12%
    -32.01%
    -18.29%
    12.56%
    91.19%
    Biontech Se
    -3.72%
    41.99%
    6.11%
    -55.22%
    226.93%
    Alnylam Pharmaceuticals, Inc.
    -3.99%
    -1.52%
    23.75%
    50.98%
    112.09%
    Vertex Pharmaceuticals Incorporated
    -12.61%
    -13.61%
    0.03%
    83.58%
    86.41%
    Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
    Chemomab Therapeutics Ltd
    NA
    NA
    NA
    -0.05
    -0.94
    -0.46
    NA
    1.2
    Regeneron Pharmaceuticals, Inc.
    17.67
    17.67
    1.06
    45.07
    0.17
    0.07
    NA
    272.04
    Biontech Se
    160.8
    NA
    0.04
    -3.11
    -0.02
    -0.01
    NA
    79.73
    Alnylam Pharmaceuticals, Inc.
    NA
    NA
    -0.49
    -0.19
    -15.01
    -0.03
    NA
    0.25
    Vertex Pharmaceuticals Incorporated
    32.84
    NA
    1.06
    0.51
    -0.03
    0.12
    NA
    60.65
    Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
    Chemomab Therapeutics Ltd
    Buy
    $32.3M
    -99.52%
    NA
    0.0%
    Regeneron Pharmaceuticals, Inc.
    Buy
    $78.5B
    91.19%
    17.67
    33.61%
    Biontech Se
    Buy
    $27.4B
    226.93%
    160.8
    -15.36%
    Alnylam Pharmaceuticals, Inc.
    Buy
    $31.4B
    112.09%
    NA
    -15.86%
    Vertex Pharmaceuticals Incorporated
    Buy
    $105.1B
    86.41%
    32.84
    -4.51%

    About Chemomab Therapeutics

    chemomab ltd. is a clinical-stage biotech company, focusing on discovery and development of innovative therapeutics for fibrosis-related diseases with large unmet need. chemomab is making great strides with its novel cm-101 proprietary platform, which hinders the fundamental function of the soluble chemokine ccl24 as a regulator of major inflammatory and fibrotic pathways in multiple fibrosis-related disorders. cm-101, the company’s lead clinical candidate, is a first-in-class monoclonal antibody that targets ccl24. chemomab has shown that cm-101 interferes with the underlying biology of fibrosis using a novel and differentiated mechanism of action. chemomab is actively advancing cm-101 into phase 2 studies to treat patients with liver fibrosis (primary sclerosing cholangitis and non-alcoholic steatohepatitis) and patients suffering from skin and lung fibrosis (systemic sclerosis).
    Organization
    Chemomab Therapeutics
    Employees
    0
    CEO
    Dr. Adi Mor George Ph.D.
    Industry
    Healthcare

    Management People of Chemomab Therapeutics

    NameTitle
    Dr. Adi Mor George Ph.D.
    Co-Founder, Chief Scientific Officer, CEO & Executive Director
    Ms. Sigal Fattal CPA, M.B.A.
    Chief Financial Officer
    Dr. Matthew B. Frankel M.B.A., M.D.
    Chief Medical Officer & VP of Drug Development
    Barbara Lindheim
    Consulting Vice President of Investor & Public Relations, Strategic Communications
    Mr. Jack Lawler
    Senior VP of Global Clinical Development Operations

    Important FAQs about investing in Chemomab Therapeutics from India :

    What is Chemomab Therapeutics share price today?

    Chemomab Therapeutics share price today stands at $1.71, Open: $1.68 ; Previous Close: $1.65 ; High: $1.75 ; Low: $1.64 ; 52 Week High: $2.55 ; 52 Week Low: $0.46. The stock opens at $1.68, after a previous close of $1.65. The stock reached a daily high of $1.75 and a low of $1.64, with a 52-week high of $2.55 and a 52-week low of $0.46.

    Can Indians buy Chemomab Therapeutics shares?

    Yes, Indians can invest in the Chemomab Therapeutics (CMMB) from India.

    With INDmoney, you can buy Chemomab Therapeutics at 0 brokerage. The step-by-step process is as follows:

    • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
    • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
    • Once funds are transferred successfully, you can buy Chemomab Therapeutics at zero transaction cost.

    How can I buy Chemomab Therapeutics shares from India?

    It is very easy to buy Chemomab Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

    Can Fractional shares of Chemomab Therapeutics be purchased?

    Yes, you can buy fractional shares of Chemomab Therapeutics with INDmoney app.

    What are the documents required to start investing in Chemomab Therapeutics stocks?

    To start investing in Chemomab Therapeutics, You will need the following documents:

    • Proof of Identification (PAN, Aadhaar etc)
    • Proof of address (Aadhaar, Voter ID etc)

    These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

    What are today’s High and Low prices of Chemomab Therapeutics

    Today’s highest price of Chemomab Therapeutics (CMMB) is $1.75.

    Today’s lowest price of Chemomab Therapeutics (CMMB) is $1.64.

    What is today's market capitalisation of Chemomab Therapeutics

    Today's market capitalisation of Chemomab Therapeutics CMMB is 32.3M

    What is the 52 Week High and Low Range of Chemomab Therapeutics

    • 52 Week High

      $2.55

    • 52 Week Low

      $0.46

    What are the historical returns of Chemomab Therapeutics?

    • 1 Month Returns

      7.74%

    • 3 Months Returns

      76.43%

    • 1 Year Returns

      223.29%

    • 5 Years Returns

      -99.52%

    Who is the Chief Executive Officer (CEO) of Chemomab Therapeutics

    Dr. Adi Mor George Ph.D. is the current Chief Executive Officer (CEO) of Chemomab Therapeutics.